Morgan Stanley Sees More Reasons to be Positive on Solazyme

In a report published Thursday, Morgan Stanley analyst Charles A. Dan reiterated an Overweight rating and $15.00 price target on

. In the report, Morgan Stanley noted, “Solazyme's competitive advantages include: 1) proprietary technology that seems to be ahead of other industrial biology companies', 2) prowess in partnering with large global chemicals/nutritionals companies, 3) cost advantage producing many of the initial products it is targeting. Our base case assumes that management executes on its existing partnerships and projects. If management hits its profitability targets, we see significant upside to our forecasts. Solazyme's oils are drop-in replacements for many natural and petroleum-derived oils, and do not require additional finishing steps to be usable in current infrastructure.” Solazyme closed on Wednesday at $11.81.